<DOC>
	<DOCNO>NCT01409018</DOCNO>
	<brief_summary>This study investigate repeated-dose pharmacokinetics safety itraconazole active metabolite hydroxyitraconazole pediatric cancer patient risk development invasive fungal disease .</brief_summary>
	<brief_title>Pharmacokinetics Itraconazole Pediatric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Pediatric patient chemotherapy , receive itraconazole . 1 . Patients significant functional deficit major organ , follow eligibility criterion may modify individual case . Heart : fractional shortening &lt; 30 % , ejection fraction &lt; 45 % Liver : total bilirubin ≥ 2 x upper limit normal ( ULN ) ; aminotransferase ≥ 3 x ULN Kidney : creatinine ≥ 2 x normal GFR ≤ 60㎖/min/1.73㎡ 2 . Patients hypersensitivity azoles . 3 . Patients , opinion investigator , may able comply safety monitoring requirement study . 4 . Pregnant nursing woman . 5 . Psychiatric disorder would preclude compliance .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pediatric</keyword>
	<keyword>cancer</keyword>
	<keyword>invasive fungal disease</keyword>
	<keyword>antifungal agent</keyword>
</DOC>